Liu Liang, Zhou Zhen-Fa, Jin Xian, Chen Yu, Hu Cui-Fen, Shen Cheng-Xing
Department of Cardiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Cardiovascular Medicine, Fuzhou First Hospital Affiliated with Fujian Medical University, Fuzhou, China.
Front Cardiovasc Med. 2025 Sep 12;12:1635557. doi: 10.3389/fcvm.2025.1635557. eCollection 2025.
Early prediction of heart failure (HF) after acute myocardial infarction (AMI) remains a clinical challenge. There is a lack of studies investigating Thymosin α1 expression levels in AMI patients and its relationship with cardiac function post-AMI.
This retrospective analysis included patients with AMI from December 2019 to February 2022. The baseline data of two groups were collected. Thymosin α1 expression level of peripheral blood plasma in AMI patients was examined by ELISA. Logistic regression analysis was applied to evaluate risk factors in-hospital cardiac dysfunction after emergency PCI in AMI patients. Receiver operating characteristic (ROC) curve was used to analyze the predictive value of the biomarker.
A total of 307 hospitalized patients were enrolled in this study, divided into AMI group ( = 274) and non-AMI group ( = 33). The expression level of thymosin α1 in the AMI group was significantly higher than in the non-AMI group. The AMI patients were divided into two subgroups based on the EF values. The sample size was 64 (EF < 50%) and 210 (EF ≥ 50%), respectively. The expression of thymosin α1 in the EF ≥ 50% group was significantly higher than EF < 50% group. Spearman's correlation analysis demonstrated that thymosin α1 was positively correlated with the EF value. Logistic multivariate analysis suggested that thymosin α1, NT-proBNP, and creatine kinase were independent predictors of cardiac function after AMI. The AUC of thymosin α1, NT-proBNP, and creatine kinase was 0.614, 0.714, and 0.724, respectively.
Thymosin α1 may serve as a potential biomarker to predict cardiac function following AMI. This study may provide novel insights into the potential therapeutic targets for HF following AMI.
急性心肌梗死（AMI）后心力衰竭（HF）的早期预测仍是一项临床挑战。目前缺乏关于AMI患者胸腺素α1表达水平及其与AMI后心脏功能关系的研究。
这项回顾性分析纳入了2019年12月至2022年2月的AMI患者。收集两组的基线数据。采用酶联免疫吸附测定（ELISA）法检测AMI患者外周血血浆中胸腺素α1的表达水平。应用逻辑回归分析评估AMI患者急诊经皮冠状动脉介入治疗（PCI）后院内发生心脏功能障碍的危险因素。采用受试者工作特征（ROC）曲线分析该生物标志物的预测价值。
本研究共纳入307例住院患者，分为AMI组（n = 274）和非AMI组（n = 33）。AMI组胸腺素α1的表达水平显著高于非AMI组。根据射血分数（EF）值将AMI患者分为两个亚组，样本量分别为64例（EF＜50%）和210例（EF≥50%）。EF≥50%组胸腺素α1的表达显著高于EF＜50%组。Spearman相关性分析表明，胸腺素α1与EF值呈正相关。逻辑多因素分析提示，胸腺素α1、N末端脑钠肽前体（NT-proBNP）和肌酸激酶是AMI后心脏功能的独立预测因子。胸腺素α1、NT-proBNP和肌酸激酶的曲线下面积（AUC）分别为0.614、0.714和0.724。
胸腺素α1可能是预测AMI后心脏功能的潜在生物标志物。本研究可能为AMI后HF的潜在治疗靶点提供新的见解。
